These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 8212364)

  • 1. [Long-term treatment with octreotide of patients with acromegaly].
    Weeke J; Orskov H; Christensen SE; Kaal A; Skjaerbaek C; Illum P; Jørgensen J; Lund E; Haubek A; Poulsen JH
    Ugeskr Laeger; 1993 Aug; 155(34):2592-8. PubMed ID: 8212364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
    Plöckinger U; Quabbe HJ
    Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
    Laczi F; Magony S; Julesz J
    Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Experience in treating acromegalic patients with long-acting octreotide].
    Szücs N; Mészáros J; Czirják S; Mondok A; Varga I; Gláz E
    Orv Hetil; 2002 May; 143(19 Suppl):1066-70. PubMed ID: 12063862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS; Musolino NR; Salgado LR; Bronstein MD
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presurgical octreotide treatment in acromegaly.
    Stevenaert A; Beckers A
    Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():18-20. PubMed ID: 8372606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly.
    Biermasz NR; Pereira AM; Smit JW; Romijn JA; Roelfsema F
    Growth Horm IGF Res; 2005 Jun; 15(3):200-6. PubMed ID: 15935982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical management of acromegaly--what and when?
    Melmed S
    Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():13-7. PubMed ID: 8372605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
    Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacodynamic analysis of octreotide in acromegalic patients.
    Comets E; Mentré F; Grass P; Kawai R; Marbach P; Vonderscher J
    Clin Pharmacol Ther; 2003 Jan; 73(1):95-106. PubMed ID: 12545148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence supporting surgery as treatment of choice for acromegaly.
    Fahlbusch R; Honegger J; Buchfelder M
    J Endocrinol; 1997 Oct; 155 Suppl 1():S53-5. PubMed ID: 9389996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
    Colao A; Pivonello R; Rosato F; Tita P; De Menis E; Barreca A; Ferrara R; Mainini F; Arosio M; Lombardi G
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.
    Turner HE; Thornton-Jones VA; Wass JA
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):224-31. PubMed ID: 15272918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of intrinsic myocardial contractility and cardiac fibrosis degree in acromegalic patients treated with somatostatin analogues: a prospective study.
    Bogazzi F; Di Bello V; Palagi C; Donne MG; Di Cori A; Gavioli S; Talini E; Cosci C; Sardella C; Brogioni S; Mariani M; Martino E
    Clin Endocrinol (Oxf); 2005 May; 62(5):590-6. PubMed ID: 15853830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Octreotide-associated biliary tract dysfunction and gallstone formation: pathophysiology and management.
    Redfern JS; Fortuner WJ
    Am J Gastroenterol; 1995 Jul; 90(7):1042-52. PubMed ID: 7611194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly.
    Plöckinger U; Dienemann D; Quabbe HJ
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1658-62. PubMed ID: 2229321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restoration of gallbladder contractility after withdrawal of long-term octreotide therapy in acromegalic patients.
    Shi YF; Zhu XF; Harris AG; Zhang JX; Deng JY
    Acta Endocrinol (Copenh); 1993 Sep; 129(3):207-12. PubMed ID: 8212985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of chronic octreotide treatment on intestinal absorption in patients with acromegaly.
    Ho PJ; Boyajy LD; Greenstein E; Barkan AL
    Dig Dis Sci; 1993 Feb; 38(2):309-15. PubMed ID: 8425442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [An observation of the secretion of growth hormone and contraction of gall bladder after long-term use of growth-inhibition excitants].
    Zhu XF; Shi YF; Gao SM
    Zhonghua Nei Ke Za Zhi; 1994 Feb; 33(2):87-91. PubMed ID: 8070297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of biliary lithogenesis in acromegalic patients with long-term octreotide (SMS 201-995) treatment].
    Buscail LE; Puel-Bousquet C; Harris AG; Tauber JP; Escourrou JR; Delvaux MM; Vaysse NM; Bayard F; Ribet A
    Gastroenterol Clin Biol; 1991; 15(11):800-4. PubMed ID: 1769469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.